IL268341B2 - Dosing plan of wnt inhibitor and anti-pd-1 antibody molecule in combination - Google Patents
Dosing plan of wnt inhibitor and anti-pd-1 antibody molecule in combinationInfo
- Publication number
- IL268341B2 IL268341B2 IL268341A IL26834119A IL268341B2 IL 268341 B2 IL268341 B2 IL 268341B2 IL 268341 A IL268341 A IL 268341A IL 26834119 A IL26834119 A IL 26834119A IL 268341 B2 IL268341 B2 IL 268341B2
- Authority
- IL
- Israel
- Prior art keywords
- day
- administered
- cancer
- seq
- treatment
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 8
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 4
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 4
- 229960002621 pembrolizumab Drugs 0.000 claims 3
- 229950010773 pidilizumab Drugs 0.000 claims 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 3
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 3
- XXYGTCZJJLTAGH-UHFFFAOYSA-N LGK974 Chemical compound C1=NC(C)=CC(C=2C(=CC(CC(=O)NC=3N=CC(=CC=3)C=3N=CC=NC=3)=CN=2)C)=C1 XXYGTCZJJLTAGH-UHFFFAOYSA-N 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458640P | 2017-02-14 | 2017-02-14 | |
| US201862616682P | 2018-01-12 | 2018-01-12 | |
| PCT/IB2018/050846 WO2018150312A1 (en) | 2017-02-14 | 2018-02-12 | Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL268341A IL268341A (en) | 2019-09-26 |
| IL268341B2 true IL268341B2 (en) | 2023-06-01 |
Family
ID=61526841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL268341A IL268341B2 (en) | 2017-02-14 | 2019-07-29 | Dosing plan of wnt inhibitor and anti-pd-1 antibody molecule in combination |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11406633B2 (enExample) |
| EP (1) | EP3582811B1 (enExample) |
| JP (3) | JP2020506159A (enExample) |
| KR (2) | KR20190112801A (enExample) |
| CN (2) | CN110267682A (enExample) |
| AU (1) | AU2018221557C1 (enExample) |
| CA (1) | CA3051989A1 (enExample) |
| IL (1) | IL268341B2 (enExample) |
| MX (1) | MX2019009630A (enExample) |
| RU (1) | RU2767533C2 (enExample) |
| TW (1) | TWI771372B (enExample) |
| WO (1) | WO2018150312A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| CA3007671A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| US20210395351A1 (en) * | 2018-09-27 | 2021-12-23 | Musc Foundation For Research Development | Pharmaceutical combination for the treatment of cancer |
| WO2020236078A1 (en) * | 2019-05-22 | 2020-11-26 | Agency For Science, Technology And Research | Pharmaceutical combination |
| CN113134090B (zh) * | 2021-03-26 | 2022-05-17 | 武汉大学中南医院 | 一种抗肿瘤药物组合物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016196218A1 (en) * | 2015-05-31 | 2016-12-08 | Curegenix Corporation | Combination compositions for immunotherapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| US20160303137A1 (en) * | 2015-04-20 | 2016-10-20 | Indiana University Research And Technology Corporation | Dual pi3k and wnt pathway inhibition as a treatment for cancer |
| CN104767366A (zh) * | 2015-04-21 | 2015-07-08 | 永济新时速电机电器有限责任公司 | 辅助变流器和车辆 |
-
2018
- 2018-02-12 WO PCT/IB2018/050846 patent/WO2018150312A1/en not_active Ceased
- 2018-02-12 CN CN201880011133.5A patent/CN110267682A/zh active Pending
- 2018-02-12 EP EP18708210.2A patent/EP3582811B1/en active Active
- 2018-02-12 MX MX2019009630A patent/MX2019009630A/es unknown
- 2018-02-12 RU RU2019128843A patent/RU2767533C2/ru active
- 2018-02-12 CN CN202311777725.7A patent/CN117752784A/zh active Pending
- 2018-02-12 AU AU2018221557A patent/AU2018221557C1/en not_active Ceased
- 2018-02-12 US US16/482,836 patent/US11406633B2/en active Active
- 2018-02-12 CA CA3051989A patent/CA3051989A1/en active Pending
- 2018-02-12 JP JP2018550764A patent/JP2020506159A/ja active Pending
- 2018-02-12 KR KR1020197026087A patent/KR20190112801A/ko not_active Ceased
- 2018-02-12 KR KR1020247000317A patent/KR20240007717A/ko not_active Ceased
- 2018-02-14 TW TW107105427A patent/TWI771372B/zh active
-
2019
- 2019-07-29 IL IL268341A patent/IL268341B2/en unknown
-
2022
- 2022-06-29 US US17/809,623 patent/US20230063366A1/en not_active Abandoned
- 2022-09-02 JP JP2022139650A patent/JP2022174157A/ja not_active Withdrawn
-
2024
- 2024-06-13 JP JP2024095809A patent/JP2024133495A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016196218A1 (en) * | 2015-05-31 | 2016-12-08 | Curegenix Corporation | Combination compositions for immunotherapy |
Non-Patent Citations (2)
| Title |
|---|
| A.NAING ET AL,, A FIRST IN HUMAN PHASE I STUDY OF THE ANTI-PD-1 ANTIBODY PDR001 IN PATIENTS WITH ADVANCED SOLID TUMORS, 20 May 2016 (2016-05-20) * |
| F. JANKU ET AL,, ABSTRACT C45: PHASE I STUDY OF WNT974, A FIRST IN CLASS PORCUPINE INHIBITOR, IN ADVANCED SOLID TUMORS, 31 December 2015 (2015-12-31) * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201836610A (zh) | 2018-10-16 |
| TWI771372B (zh) | 2022-07-21 |
| KR20190112801A (ko) | 2019-10-07 |
| US20230063366A1 (en) | 2023-03-02 |
| AU2018221557C1 (en) | 2021-10-14 |
| AU2018221557B2 (en) | 2021-03-11 |
| RU2019128843A3 (enExample) | 2021-05-17 |
| EP3582811B1 (en) | 2024-07-10 |
| CN117752784A (zh) | 2024-03-26 |
| CA3051989A1 (en) | 2018-08-23 |
| MX2019009630A (es) | 2019-11-08 |
| WO2018150312A1 (en) | 2018-08-23 |
| US20190365746A1 (en) | 2019-12-05 |
| EP3582811A1 (en) | 2019-12-25 |
| KR20240007717A (ko) | 2024-01-16 |
| JP2020506159A (ja) | 2020-02-27 |
| IL268341A (en) | 2019-09-26 |
| US11406633B2 (en) | 2022-08-09 |
| RU2767533C2 (ru) | 2022-03-17 |
| AU2018221557A1 (en) | 2019-08-15 |
| JP2022174157A (ja) | 2022-11-22 |
| JP2024133495A (ja) | 2024-10-02 |
| CN110267682A (zh) | 2019-09-20 |
| RU2019128843A (ru) | 2021-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230063366A1 (en) | Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination | |
| JP6663493B2 (ja) | がんの処置に使用するための５−ブロモ−２，６−ジ−（１ｈ−ピラゾール−１−イル）ピリミジン−４−アミン | |
| US11001628B2 (en) | Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer | |
| US20180177872A1 (en) | Combination of PD-1 antagonist with an EGFR inhibitor | |
| WO2017091577A1 (en) | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment | |
| US20220306737A1 (en) | Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis | |
| JP2022548145A (ja) | 免疫療法の化合物および方法 | |
| BR112019017696A2 (pt) | programa de dosagem para uma combinação de ceritinib e uma molécula de anticorpo anti-pd-1 | |
| US20230172920A1 (en) | Dosing regimen for treating a disease modulated by csf-1r | |
| JP2025527535A (ja) | 抗ｃｃｒ８抗体およびその使用 | |
| RU2835316C1 (ru) | Режим введения доз для лечения заболевания, модулируемого csf-1r | |
| US20250215087A1 (en) | Combination therapy of kras inhibitor and treg depleting agent | |
| HK40011167B (en) | Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination | |
| HK40011167A (en) | Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination | |
| JP6964113B2 (ja) | がんの処置に使用するための５−ブロモ−２，６−ジ−（１ｈ−ピラゾール−１−イル）ピリミジン−４−アミン | |
| WO2025101807A1 (en) | Treatment of gliomas with chimeric antigen receptor t cells |